Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.

← catalyst calendar

NCT06847464

Sponsored by Enanta Pharmaceuticals, Inc (industry) · ENTA — their whole pipeline →.

Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Basic science
Enrollment
48actual
Sites
1
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2025-01-27actualWhen the study began enrolling
Primary completion2025-05-24actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-06-01actualThe whole study's end, after follow-up
First posted2025-02-26actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-07-01actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • RSV Infection
  • Drug Drug Interaction (DDI)

Interventions

  • Drug: EDP-323
  • Drug: Itraconazole
  • Drug: EDP-323
  • Drug: carbamazepine
  • Drug: EDP-323
  • Drug: Quinidine
  • Drug: EDP-323
  • Drug: fluconazole

Primary outcomes

what the primary-completion date above is the date OF
Cmax of EDP-323 with and without coadministration with Itraconazole
measured Day 1 through Day 19
AUC of EDP-323 with and without coadministration with Itraconazole
measured Day 1 through Day 19
Cmax of EDP-323 with and without coadministration with Carbamazepine
measured Day 1 through Day 28
AUC of EDP-323 with and without coadministration with Carbamazepine
measured Day 1 through Day 28
Cmax of EDP-323 with and without coadministration with Quinidine
measured Day 1 through Day 13
AUC of EDP-323 with and without coadministration with Quinidine
measured Day 1 through Day 13
Cmax of EDP-323 with and without coadministration with fluconazole
measured Day 1 through Day 19
AUC of EDP-323 with and without coadministration with fluconazole
measured Day 1 through Day 19

Permalink · ENTA's whole pipeline · Catalyst calendar · Every registered study · What changed